

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(MBHB00,814-A 400.034)

In the Applica	McSwiggen, et al.)
Serial No.	09/927,046))
Filed:	August 9, 2001)) `
For:	METHOD AND REAGENT FOR THE INHIBITION OF CALCIUM ACTIVATED CHLORIDE CHANNEL-1 (CLCA-1))))

Examiner: TB

Art Unit: 164

Washington, D.C. 20231 Sir:

Commissioner for Patents

TRANSMITTAL LETTER


In regard to the above identified application:

- 1. We are transmitting herewith the attached papers for the above identified new patent application:
 - ☐ Information Disclosure Statement;
 - Copies of IDS Citations for S/N 09/927,046 (3 U.S. Patent Applications, 11 U.S. Patents, 31 Foreign Patents and 172 Other References);
 - Information Disclosure Statement (IDS) PTO-1449 Form; and
 - Return Receipt Postcard.
- 2. With respect to additional fees, no additional fee is required.
- 3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
- 4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in a box addressed to Commissioner for Patents, Washington, D.C. 20231 on January 31, 2002.

Date: January 31, 2002

By:

Andrew W. Williams Reg. No. 48,644



#5/K.T. 4/26 I.D.S.

Examiner:

Art Unit: 1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB00,814-A 400.034)

CH CENTER 1600/29	APR 0 9 2002	RECEIVED
8		

In the Application of:

McSwiggen, et al.

Serial No. 09/927,046

Filed: August 9, 2001

For: METHOD AND REAGENT FOR THE
INHIBITION OF CALCIUM ACTIVATED
CHLORIDE CHANNEL-1 (CLCA-1)

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to the duty of disclosure provided by 37 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make the following references of record in the above-identified application. Copies of all references cited are also listed in the PTO-1449 form enclosed herewith. It is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation

is intended as to the relative importance of any portion of the references. This Statement not a representation that the cited references have effective dates early enough to be "prior age"

the meaning of 35 U.S.C. sections 102 or 103.



CITED REFERENCES

U.S. PATENT APPLICATION DOCUMENTS

No.	Document Number	Filing Date	Name
1.	60/101,074	9/21/98	Hartmann, et al.
2.	60/082,404	4/20/98	Thompson et al.
3.	09/406,643	9/27/99	Warburg
1			

U. S. PATENT DOCUMENTS

4,987,071 5,334,711 5,525,468 5,624,803	Cech et al. Sproat et al. McSwiggen Noonberg et al.	1/22/91 8/2/94 6/11/96
5,525,468 5,624,803	McSwiggen	6/11/96
5,624,803		
	Noonberg et al	4/20/07
5 (07 052	1 100110015 of all	4/29/97
5,627,053	Osman et al.	5/6/97
5,631,359	Chowrira et al.	5/20/97
5,633,133	Long et al.	5/27/97
5,672,695	Eckstein et al.	9/30/97
5,716,824	Beigelman et al.	2/10/98
5,849,902	Arrow et al.	12/15/98
6,001,311	Brennan	12/4/99
	5,849,902	5,849,902 Arrow et al.

FOREIGN PATENT DOCUMENTS

No.	Document Number	Name	Date	Country
15.	0 360 257 A2	Hampel et al.	28.03.90	EO

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, Fl. 32 Chicago, IL 60606

Telephone: (312) 913-0001

MBHB00,814-A RPI NO. 400.034

S/N: 09/927,046 Filing Date: 08/09/01



TECH CENTER 1600/2900

	<u> </u>		IECH	CENTER 1600/29
RADEMARKS	Document Number	Name	Date	Country
16.	91/03162	Rossi et al.	21.03.91	WO/PCT
17.	92/07065	Eckstein et al.	30.04.92	WO/PCT
18.	93/15187	Usman et al.	05.08.93	WO/PCT
19.	93/23057	Thompson et al.	25.11.93	WP/PCT
20.	93/23569	Draper et al.	25.11.93	WO/PCT
21.	94/02595	Sullivan et al.	03.02.94	WO/PCT
22.	95/04818	Draper et al.	16.02.95	WO/PCT
23.	95/11304	Usman et al.	27.04.95	WO/PCT
24.	95/13380	Draper et al.	18.05.95	WO/PCT
25.	95/23225	Stinchcomb et al.	31.08.95	WO/PCT
26.	96/10390	Ansell et al.	11.04.96	WO/PCT
27.	96/10391	Choi et al.	11.04.96	WO/PCT
28.	96/10392	Holland et al.	11.04.96	WO/PCT
29.	96/18736	Beigelman et al.	20.06.96	WO/PCT
30.	96/22689	Pyle et al.	01.08.96	WO/PCT
31.	97/26270	Wincott et al.	24.07.97	WO/PCT
32.	97/35562	Illum et al.	02/10/97	WO/PCT
33.	98/13526	Woolf	02.04.98	WO/PCT
34.	98/28317	rpelsky et al.	02.07.98	WO/PCT
35.	98/43993	eaker	08.10.98	WO/PCT
36.	98/50530	Jarvis et al.	12.11.98	WO/PCT
37.	98/58058	Ludwig et al.	23.12.98	WO/PCT
38.	99/04819	Klimuk et al.	04.02.99	WO/PCT
39.	99/05094	Beigelman et al.	22.07.98	WO/PCT
40.	99/16871	Eckstein et al.	08.04.99	WO/PCT
41.	99/44620	Holroyd et al.	10/09/99	WO/PCT



			•	ECH CENTER 16
DEMENTO.	Document Number	Name	Date	Country
42.	99/54459	Thompson et al.	28.10.99	WO/PCT
43.	99/55857	Beigelman et al.	28.04.99	WO/PCT
44.	99/60010	Bennett et al.	25.11.99	WO/PCT
45.	99/60166	Bennett et al.	25/11/99	WO/PCT

OTHER DOCUMENTS

No.	
46.	Abramovitz et al., "Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site," Science 271:1410-1413 (1996)
47.	Akhtar and Juliano, "Cellular uptake and intracellular fate of antisense oligonucleotides," Trends in Cell Biology 2:139-144 (1992)
48.	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <u>Nucleic Acids Research</u> 26:4910-4916 (1998)
49.	Banerjee and Turner, "The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme," <u>Biochemistry</u> 34:6504-6512 (1995)
50.	Beaudry et al., "Directed Evolution of an RNA Enzyme," Science 257:635-641 (1992)
51.	Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <u>J. Biol. Chem.</u> 270:25702-25708 (1995)
52.	Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," Nucleosides & Nucleotides 16:951-954 (1997)
53.	Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Aproach to Iterative Solid-Phase Synthesis," <u>Bioconjugate Chem.</u> 8:204-212 (1997)
54.	Berzal-Herranz et al., "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," EBMO J. 12:2567-2574 (1993)
55.	Berzal-Herranz et al., "In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed clevage and ligation reactions," Genes & Development 6:129-134 (1992)
56.	Bevilacqua et al., "A Mechanistic Framework for the Second Step of Splicing Catalyzed by the <i>Tetrahymena</i> Ribozyme," Biochemistry 35:648-658 (1996)
57.	Boado, "Antisense drug delivery through the blood-brain barrier," Advanced Drug Delivery Reviews 15:73-107 (1995)
58.	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, Fl. 32 Chicago, IL 60606 Telephone: (312) 913-0001

MBHB00,814-A RPI NO. 400.034 S/N: 09/927,046 Filing Date: 08/09/01

4



61F	()	RECEIV	ED
FEB 2	6 2002	APR 0 9 20	002
ENTR T	North	TECH CENTER 16	600/2900
311	39.	Bongartz et al., "Improved biological activity of antisense oligonucleotides conjugated to a	-0,-000
•		fusogenic peptide," Nucleic Acids Research 22:4681-4688 (1994)	
Ϊ,	60.	Breaker et al., "A DNA enzyme with Mg ² -dependent RNA phosphoesterase activity,"	
		<u>Chemistry & Biology</u> 2(10):655-660 (1995)	
	61.	Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus	
		iterative selection methods," <u>TIBTECH</u> 12:268-275 (1994)	

Biochemistry 35:14090-14097 (1996) (volume no mistakenly listed as 6)

Breaker, "Are engineered proteins getting competition from RNA?" Current Opinion in

Automated Combinatorial Solid-Phase Organic Synthesis," Biotechnology and Bioendineering

Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates."

Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide

Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently

Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to

Burlina et al., "Chemical Engineering of Rnase Resistant and Catalytically Active Hammerhead Ribozymes," Bioorganic & Medicinal Chemistry 5:1999-2010 (1997)

Cech, "Ribozymes and Their Medical Implications," JAMA 260:3030-3034 (1988) Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the

hammerhead ribozyme domain," Nucleic Acids Research 23(20):4092-4096 (1995)

Sequenced HIV-1 Isolates," Nucleic Acids Research 20:4581-4589 (1992)

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, Fl. 32 Chicago, IL 60606 Telephone: (312) 913-0001

62.

63.

64.

65.

66.

67.

68.

69.

70.

71.

72.

73.

74.

75.

76.

77.

78.

354:320-322 (1991)

<u>Trends In Genetics</u> 12:510-515 (1996)

Chem, 270: 31016-31026 (1995).

Biotechnology 7:442-448 (1996)

(Combinatorial Chemistry) 61:33-45 (1998)

Analogs," Methods in Enzymology 211:3-19 (1992)



TECH CENTER 1600/2900

Nost	TECH CENTER 1600/29
APS	Daniels et al., "Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative Analysis of <i>in Vitro</i> Reaction Rates and Products," J. Mol. Biol. 256:31-49 (1996)
80.	Dreyfus, "Restriction Ribozymes?" Einstein Quarterly Journal of Biology and Medicine 6:92-93 (1988)
81.	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <u>Journal of Virology</u> 66:1432-1441 (1992)
82.	Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," Proc. Natl. Acad. Sci. USA 89:504-508 (1992)
83.	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <i>Biopolymers</i> 48:39-55 (1998)
84.	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," Nature 365:566-568 (1993)
85.	Eible et al., "Cloning and Characterization of Lung-Endothelial Cell Adhesion Molecule-1 Suggest It Is an Endothelial Chloride Channel," J. Biol. Chem., 272: 27853-27861 (1997).
86.	Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," <u>Proc. Natl. Acad. Sci. USA</u> 87:6743-6747 (1990)
87.	Emerich et al., "Biocompatability of Poly (DL-Lactide-co-Glycolide) Microsheres Implanted Into the Brain," Cell Transplantation 8:47-58 (1999)
88.	Feldstein et al., "Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA," Gene 82:53-61 (1989)
89.	Filion and Phillips, "Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells," <i>Biochimica et Biophysica Acta</i> 1329:345-356 (1997)
90.	Forster and Altman, "External Guide Sequences for an RNA Enzyme," Science 249:783-786 (1990)
91.	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <u>Proc.</u> Natl. Acad. Sci. USA 83:9373-9377 (1986)
92.	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <u>Nucleic Acids Research</u> 21:2867-2872 (1993)
93.	Good et al., "Expression of small, therapuetic RNAs in human nuclei," Gene Therapy 4:45-54 (1997)
94.	Grasby et al., "Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA," Biochemistry 34:4068-4076 (1995)
95.	Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups," Chemistry & Biology 2:761-770 (1995)
96.	Gruber et al., "Genomic Cloning, Molecular Characterization, and Functional Analysis of Human CLCA1, the First Human Member of the Family of Ca ²⁺ -Activated Cl ⁻ Channel Proteins," Genomics, 54, 200-214 (1998)



10	IPE
FEB	2 6 2002 6
THE STATE OF THE S	No., &

F	y
No. of	
ADBMAR!	or and the marine carefully benefit to emercate challeng (modes) to wrately empressed in
	secretory epithelia and in other select tissues," <u>Histochem. Cell Biol.</u> , 110, 43-49 (1998)
98.	Gruber et al., "Molecular Cloning and Transmemnbrane Structure of hCLCA2 from Human
	Lung, Trachea, and Mammary Gland,", Am. J. Physiol., 276: C1261-C1270 (1999)
99.	Gruber et al., "Tumorigenicity of Human Breast Cancer is Asociated with Loss of the Ca ²⁺ -
100	activated Chloride Channel CLCA2, Cancer Res., 59: 5488-5491 (1999).
100.	Guerrier-Takada et al., "The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the
101	Enzyme," <u>Cell</u> 35:849-857 (1983)
101.	Guo and Collins, "Efficient trans-cleavage of a stem-loop RNA substrate by a ribozyme
100	derived from Neurospora VS RNA," EMBO J. 14:368-376 (1995)
102.	Hampel and Tritz, "RNA Catalytic Properties of the Minimum (-)sTRSV Sequence,"
100	Biochemistry 28:4929-4933 (1989)
103.	Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence
104	Requirement for Substrate RNA," Nucleic Acids Research 18:299-304 (1990)
104.	Harris et al., "Identification of phosphates involved in catalysis by the ribozyme RNase P
107	RNA," <u>RNA</u> 1:210-218 (1995)
105.	Hartmann et al., "Spontaneous and Cationic Lipid-Mediated Uptake of Antisense
	Oligonucleotides in Human Monocytes and Lymphocytes," The Journal of Pharmacology and
106	Experimental Therapeutics 285:920-928 (1998)
106.	Haseloff and Gerlach, "Sequences required for self-catalysed cleavage of the satellite RNA of
105	tobacco ringspot virus," Gene 82:43-52 (1989)
107.	Haseloff and Gerlach, "Simple RNA Enzymes with New and Highly Specific
100	Endoribonuclease Activities," Nature 334:585-591 (1988)
108.	Hegg et al., "Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin
100	Ribozymes," <u>Biochemistry</u> 34:15813-15828 (1995)
109.	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme
	1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active
110	Site," <u>Biochemistry</u> 29:10159-10171 (1990)
110.	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme.
	2. Kinetic Description of the Reaction of an RNA Substrate That Forms a Mismatch at the
111	Active Site," Biochemistry 29:10172-10180 (1990)
111.	Hertel et al., "A Kinetic Thermodynamic Framework for the Hammerhead Ribozyme
112	Reaction," Biochemistry 33:3374-3385 (1994)
112.	Hertel et al., "Numbering System for the Hammerhead," <u>Nucleic Acids Research</u> 20:3252
112	(1992)
113.	Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic
114	Methods," VCH, 331-417 (1995) Inhipute et al. "Physical Chamistry Chamataristics and Diadiatribution of Palacethalana
114.	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene
	glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," <u>Chem. Pharm. Bull.</u>
115	43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
115.	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti Songe BNA." Science 220:245-252 (1985)
L	Endogeneous Genes by Anti-Sense RNA," Science 229:345-352 (1985)

APR 0 9 2002 TECH CENTER 1600/2900

E MADEN		
116.	Jaeger et al., "Improved Predictions of Secondary Structures for RNA," Proc. Natl. Acad. Sci.	
ļ	<u>USA</u> 86:7706-7710 (1989)	
117.	Jeffries and Symons, "A Catalytic 13-mer Ribozyme," Nucleic Acids Research 17:1371-1377	
	(1989) (also referred to as Jefferies)	
118.	Jolliet-Riant and Tillement, "Drug transfer acorss the blood-brain barrier and improvement of	
	brain delivery," Fundam. Clin. Pharmacol. 13:16-26 (1999)	
119.	Joseph et al., "Substrate selection rules for the hairpin ribozyme determined by in vitro	
	selection, mutation, and analysis of mismatched substrates," Genes & Development 7:130-138	
	(1993)	
120.	Joyce et al., "Amplification, mutation and selection of catalytic RNA," Gene 82:83-87 (1989)	
121.	Joyce, "Directed Molecular Evolution," Scientific American 267:90-97 (1992)	
122.	Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their	
	Incorporation in Hammerhead Ribozymes," <u>Tetrahedron Letters</u> 39:1131-1134 (1998)	
123.	Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme,"	
	Antisense Research & Development 2:3-15 (1992)	
124.	Kent et al., "Lung Disease in Mice with Cystic Fibrosis,", <u>J. Clin. Invest.</u> , 100(12): 3060-3069	
100	(1997).	
125.	Kim and Cech, "Three-dimensional model of the active site of the self-splicing rRNA	
106	precursor of Tetrahymena," Proc. Natl. Acad. Sci. USA 84:8788-8792 (1987)	
126.	Knitt et al., "ph Dependencies of the <i>Tetrahymena</i> Ribozyme Reveal an Unconvential Origin	
127	of an Apparent pK _a ," Biochemistry 35:1560-1570 (1996)	
127.	Kore, et al., "Sequence specificity of the hammerhead ribozyme revisistsed; the NIH rule", Nucleic Acids Research, 26(18):4116-4120 (1998).	
128.	Kronenwett et al., "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells	
	is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset," Blood	
	91:852-862 (1998)	
129.	Kumar and Ellington, "Artificial evolution and natural ribozymes," FASEB J. 9:1183-1195	
	(1995)	
130.	Lasic and Papahadjopoulos, "Liposomes Revisited," Science 267:1275-1276 (1995)	
131.	L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α-	
	Lactalbumin mRNA Levels in C1271 Mouse," EMBO J. 11:4411-4418 (1992)	
132.	Li and Altman, "Cleavage by RNase P of gene N mRNA reduces bacteriophage λ burst size,"	
	Nucleic Acids Research 24:835-842 (1996)	
133.	Li et al., "Thermodynamic and Activation Parameters for Binding of a Pyrene-Labeled	
	Substrate by the <i>Tetrahymena</i> Ribozyme: Docking is Not Diffusion-Controlled and is Driven	
124	by a Favorable Entropy Change," Biochemistry 34:14394-14399 (1995)	
134.	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA	
125	Polymerase," Methods Enzymol. 217:47-66 (1993)	
135.	Limbach et al., "Summary: the modified nucleosides of RNA," <u>Nucleic Acids Research</u>	
136.	22(12):2183-2196 (1994) Ligacely et al. "Automotic Identification of Crown Ligacely et al. "Automotic Identification of Crown Ligacely et al."	
136.	Lisacek et al., "Automatic Identification of Group I Intron Cores in Genomic DNA	
	Sequences," <u>J. Mol. Biol.</u> 235:1206-1217 (1994)	

Telephone: (312) 913-0001



No of	TECH CENTER 1001
Nongt	Lisziewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by
1.	Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for
138.	Gene Therapy in AIDS," Proc. Natl. Acad. Sci. U.S.A. 90:8000-8004 (1993) Livet al. "Cationia Linguage mediated Introveneus Cone Policy II. Piel Chem.
136.	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," J. Biol. Chem. 270(42):24864-24870 (1995)
139.	
139.	Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular
140.	hammerhead RNAs with stem II deletions," Proc. Natl. Acad. Sci. USA 91:6977-6981 (1994)
140.	Ma and Wei, "Enhanced Delivery of Synthetic Oligonucleotides to Human Leukaemic Cells by
141	Liposomes and Immunoliposomes," Leukemia Research 20:925-930 (1996)
141.	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense
1.42	RNA," Proc. Natl. Acad. Sci. USA 83:399-403 (1986)
142.	McKay, "Structure and function of the hammerhead ribozyme: an unfinished story," <u>RNA</u>
142	2:395-403 (1996)
143.	Mesmaeker et al, "Novel Backbone Replacements for Oligonucleotides," American Chemical
144	Society, pp. 24-39 (1994)
144.	Metzger and Nyce, "Molecular mechanisms in allergy and clinical immunology," J. Allergy
1.45	Clin. Immunol., 104(2, Pt. 1), 260-266 (1999)
145.	Michel and Westhof, "Slippery substratrates," Nat. Struct. Biol. 1:5-7 (1994)
146.	Michel et al., "Structure and Activities of Group II Introns," <u>Annu. Rev. Biochem.</u> 64:435-461
1.47	(1995)
147.	Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme
	that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and
140	Structure/Function Relationships," Biochemistry 34:2965-2977 (1995)
148.	Milligan and Uhlenbeck, "Synthesis of Small RNAs Using T7 RNA Polymerase," Methods
140	Enzymol. 180:51-62 (1989)
149.	Mitra et al., "A mammalian 2-5A system functions as an antiviral pathway in transgenic
150	plants," <u>Proc. Natl. Acad. Sci. USA</u> 93:6780-6785 (1996)
150.	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the
151	Splice Sites," <u>Science</u> 256:992-996 (1992)
151.	Mukhopadhyay et al., "Antisense Regulation of Oncogenes in Human Cancer," <u>Critical</u>
152	Reviews in Oncogenesis 7:151-190 (1996)
152.	Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for
153.	Improved Cleavage," Biochemistry 33:1271-1277 (1994) Nothern and Smith "Postriction Endomylogogia the Analysis and Restructuring of DNA
133.	Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA
154.	Molecules," Ann. Rev. Biochem. 44:273-293 (1975)
134.	Noonberg et al., <i>In vivo</i> generation of highly abundant sequence-specific oligonucleotides for
155.	antisense and triplex gene regulation," <u>Nucleic Acids Research</u> 22(14):2830-2836 (1994)
133.	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun'
156.	Type Ribozyme-trimming Plasmid," <u>Nucleic Acids Symp. Ser.</u> 27:15-16 (1992)
130.	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin
157	Ribozyme," <u>Proc. Natl. Acad. Sci. USA</u> 89:10802-10806 (1992)
157.	Orgel, "Selection in vitro," Proc. R. Soc. London B. 205:435-442 (1979)



APR 0.9.2002

TECH CENTER 1600/2900

	TECH CENTER
No.	RADEMARK
158.	Pan et al., "Probing of tertiary interactions in RNA: 2'-Hydroxyl-base contacts between the Rnase P and pre-tRNA," Proc. Natl. Acad. Sci. USA 92:12510-12514 (1995)
159.	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo," Proc. Natl. Acad. Sci. USA 92:5592-5596 (1995)
160.	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," Nature 344:565-567 (1990) (often mistakenly listed as Perrault)
161.	Perrotta and Been, "A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA," Nature 350:434-436 (1991)
162.	Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence," <u>Biochemistry</u> 31:16-21 (1992)
163.	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," Science 253:314-317 (1991)
164.	Puttaraju et al., "A circular trans-acting hepatitis delta virus ribozyme," <u>Nucleic Acids</u> Research 21:4253-4258 (1993)
165.	Pyle et al., "Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate," <u>Biochemistry</u> 33:2716-2725 (1994)
166.	Ran and Benos, "Immunopurification and Structural Analysis of a Putative Epithelial C1-Channel Protein Isolated from Bovine Trachea," J. Biol. Chem, 267: 3618-3625 (1992)
167.	Robertson et al., "Purification and Properties of a Specific <i>Escherichia coli</i> Riobnuclease which Cleaves a Tyrosine Transfer Ribonucleic Acid Precursor," J. Biol. Chem. 247:5243-5251 (1972)
168.	Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," Aids Research and Human Retroviruses 8:183-189 (1992)
169.	Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," <u>Proc. Natl. Acad. Sci. USA</u> 94:4262-4266 (1997)
170.	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" Science 247:1222-1225 (1990)
171.	Saville and Collins, "A Site-Specific Self-Cleavage Reaction Performed by a Novel RNA In Neurospora Mitochondria," Cell 61:685-696 (1990)
172.	Saville and Collins, "RNA-Mediated Ligation of Self-Cleavage Products of a <i>Neurospora</i> Mitochondrial Plasmid Transcript," <u>Proc. Natl. Acad. Sci. USA</u> 88:8826-8830 (1991)
173.	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <u>Proc. Natl. Acad. Sci. USA</u> 88:10591-10595 (1991)
174.	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β-cyanoethyl protected ribonucleoside phosphoramidites," Nucl Acids Res. 18:5433-5441 (1990)
175.	Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," <i>The Journal of Biological Chemistry</i> 274:21783-21789 (1999)
176.	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," Nucleic Acids Research 24:573-581 (1996)
177.	Scott et al., "The crystal structure of an All-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage," Cell 81:991-1002 (1995)
	men Hulbert & Berghoff 10 MBHB0 PD Drive F1 32

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, Fl. 32 Chicago, IL 60606

Telephone: (312) 913-0001

MBHB00,814-A RPI NO. 400.034

S/N: 09/927,046 Filing Date: 08/09/01



No.	TECH CENTER 1600/2
178.	Shabarova et al., "Chemical ligation of DNA: The first non-enyzmatic assembly of a
	biologically active gene," Nucleic Acids Research 19:4247-4251 (1991)
179.	Shapiro, "Animal Models for Chronic Obstructive Pulmonary Disease; Age of Klotho and
	Marlboro Mice," Am. J. Respir. Cell Mol. Biol., 22(1): 4-7 (2000).
180.	Stein, "Does antisense exist," Nature Medicine 1(11):1119-1121 (1995)
181.	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really
	Magical?" <u>Science</u> 261:1004-1288 (1993)
182.	Strobel et al., "Exocyclic Amine of the Conserved G·U Pair at the Cleavage Site of the
	Tetrahymena Ribozyme Contributes to 5'-Splice Site Selection and Transition State
	Stabilization," Biochemistry 35:1201-1211 (1996)
183.	Strobel et al., "Minor Groove Recognition of the Conserved G·U Pair at the Tetrahymena
	Ribozyme Reaction Site," Science 267:675-679 (1995)
184.	Sullenger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-
	splicing," <u>Nature</u> 371:619-622 (1994)
185.	Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction o
	Viral RNA," <u>Science</u> 262:1566-1569 (1993)
186.	Szostak, "In Vitro Genes," TIBS 17:89-93 (1993)
187.	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used
ļ	both in vitro in place of run-off and (G)-free transcriptions and in vivo as multi-sequences
	transcription vectors," Nucleic Acids Research 19:5125-5130 (1991)
188.	Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro
100	selection," RNA 3:914-925 (1997)
189.	Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-
100	based RNA polymerase III promoter," <u>Nucleic Acids Research</u> 23:2259-2268 (1995)
190.	Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense
101	chimera," Proc. Natl. Acad. Sci. USA 90:1300-1304 (1993)
191.	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <u>J.</u> Am. Chem. Soc. 109:3783-3785 (1987)
192.	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p.
1 1/2.	cross the blood-brain barrier and specifically reduce gene expression," <i>Proc. Natl. Acad. Sci.</i>
	USA 96:7053-7058 (1999)
193.	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal
1,73.	cells in vivo," FEBS Letters 421:280-284 (1998)
194.	Uhlenbeck, "A Small Catalytic Oligoribonucleotide," Nature 328:596-600 (1987) (this is listed
1,71.	as Nature 327 in the various specifications, but it is actually 328)
195.	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," Chemica
1,5.	Reviews 90:544-584 (1990)
196.	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," TIBS 17:334-339 (1992)
197.	Usman and McSwiggen, "Ch. 30 - Catalytic RNA (Ribozymes) as Drugs," Annual Reports in
	Medicinal Chemistry 30:285-294 (1995)
	No. of the second secon





TECH CENTER 1600/2900

	TEOH OLIVILII 1000/290
No.	TO TRADEMANTE
198.	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-
	Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support:
	Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an Escherichia coli
	Formylmethoionine tRNA," <u>J. Am. Chem. Soc.</u> 109:7845-7854 (1987)
199.	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease
	resistance," Nucleic Acids Syposium Series 31:163-164 (1994)
200.	Usman et al., "Hammerhead ribozyme engineering," Current Opinion in Structural Biology
	1:527-533(1996)
201.	Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by in Vitro
	Selection," <u>Biochemistry</u> 36:6495-6501 (1997)
202.	Van Doorninck et al., "A mouse model for the cystic fibrosis ΔF508 mutation," EMBO J.,
	14(18), 4403-11 (1995)
203.	Vassar et al., "β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the
	Transmembrane Aspartic Protease BACE," Science 286:735-741 (1999)
204.	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," Nucleic
	Acids Research 21:3249-3255 (1993)
205.	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," Annu.
	Rev. Biochem. 67:99-134 (1998)
206.	Vyle et al., "Sequence- and Strand-Specific Cleavage in Oligodeoxyribonucleotides and DNA
	Containing 3'-Thiothymidine," Biochemistry 31:3012-3018 (1992)
207.	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes,"
	Nucleic Acids Research 23(14):2677-2684 (1995)
208.	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," Methods in
	Molecular Biology 74:59-69 (1997)
209.	Wu-Pong, "Oligonucleotides: Opportunities for Drug Therapy and Research, "Biopharm,
	November 1994.
210.	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human
	Immunodeficiency Virus Type 1," Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993)
211.	Yuan et al., "Targeted cleavage of mRNA by human RNase P," Proc. Natl. Acad. Sci. USA
	89:8006-8010 (1992)
212.	Zarrinkar and Williamson, "The P9.1-P9.2 peripheral extension helps guide folding of the
!	Tetrahymena ribozyme," Nucleic Acids Research 24:854-858 (1996)
213.	Zaug et al., "The Tetrahymena Ribozyme Acts Like an RNA Restriction Endonuclease,"
	Nature 324:429-433 (1986)
214.	Zeiher et al., "A Mouse Model for the ΔF508 Allele of Cystic Fibrosis," 1995, J. Clin Invest.,
	96(4), 2051-64
215.	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA
	Polymerase," Mol. Cell. Biol. 10:4529-4537 (1990)
216.	Zimmerly et al., "A Group II Intron RNA is a Catalytic Component of a DNA Endonuclease
	Involved in Intron Mobility," Cell 83:529-538 (1995)
217.	Zhu et al., Blocking of Lung Endothelial Cell Adhesion Molecule-1 (Lu-ECAM-1) Inhibits
	Murine Melanoma Lung Metastasis,) 1992, J. Clin Invest., 89, 1718-1724

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, Fl. 32 Chicago, IL 60606 Telephone: (312) 913-0001

MBHB00,814-A RPI NO. 400.034 S/N: 09/927,046 Filing Date: 08/09/01 any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Date: January 31, 2002

Bv.

Andrew W. Williams

Registration No. 48,644